Melanoma Treatment Market Revenue Opportunies by Major Players Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd., Genetech Inc., Novartis AG, Polynoma LLC, AstraZeneca, Amgen Inc., Sanofi

Several drugs in the market have already received FDA approval for melanoma treatment and some are under development. Drugs such as seviprotimut-L by Polynoma’s, talimogene laherparepvec (T-VEC) by Amgen Inc., and zelboraf, by Roche and Genetech together for the treatment of cutaneous melanoma are under development. Selumetinib is under development by AstraZeneca for the treatment of ocular melanoma. In 2011, Yervoy, a monoclonal antibody drug was developed by Bristol-Myers Squibb for the treatment of melanoma and it is the first drug to receive FDA approval.

Download PDF Brochure of Research Report: www.coherentmarketinsights.com/insight/request-pdf/719

Immunotherapy drugs include opdivo and keytruda, which got FDA approval and created new opportunities in melanoma treatment market. When chemotherapy fails to deliver results, targeted therapy is used, which include BRAF inhibitors. Targeted therapy has limited side effects in comparison with chemotherapy. According to Cancer Research Institute, in 2016, there were around 76,000 people diagnosed with melanoma in the U.S. The development of novel drugs and combination therapy with limited side effects and better survival rates is expected to fuel the melanoma treatment market growth. The increased focus on personalized medicine with a huge investment in anti-melanoma drugs is expected to create new opportunities in near future. However, high price of combination therapies and clinical trial with side effects act as restraints for the melanoma treatment market.

According to the American Academy of Dermatology 2015 report, the prevalence of melanoma is increasing and spreads to other body parts as well. As it spreads to other body parts, its treatment becomes much more complex. The rare genetic conditions such as xeroderma pigmentosum also increase the risk of melanoma and it is diagnosed with the biopsy of any skin lesion.

Melanoma treatment market, based on geography, is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America dominates the melanoma treatment market due to the high prevalence of melanoma in the region along with well-developed healthcare facilities and increased research and development on melanoma drugs. Moreover, reimbursement policy and increase in per capita income are expected to fuel the melanoma treatment market. Europe is the second largest market and is expected to grow significantly in near future due to increase in melanoma cases and development of novel therapies. Asia Pacific is expected to exhibit moderate growth due to fewer cases of skin cancer, lack of awareness, and high cost of melanoma drugs.

Get Request Sample Copy of Research Report: www.coherentmarketinsights.com/insight/request-sample/719

Some of the key players identified across the value chain of global melanoma treatment market are Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd., Genetech Inc., Novartis AG, Polynoma LLC, AstraZeneca, Amgen Inc., Sanofi, Merck & Co. Inc., and Takeda Pharmaceutical Company.

Melanoma Treatment Market Taxonomy:

The global melanoma treatment market is segmented as follows;

By Melanoma Type;

Cutaneous Melanoma
Mucosal Melanoma
Ocular Melanoma
By Therapy;

Chemotherapy
Immunotherapy
Targeted Therapy
Surgical Treatment
Pharmacological Treatment

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154

This release was published on openPR.